Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer

References

• Aina OH, Sroka TC, Chen ML, Lam KS. (2002). Therapeutic cancer targeting peptides. Biopolymers 66:184.
   PubMed Web of Science ®Google Scholar
• Aye MM, Ma C, Lin H, et al. (2004). Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts. Int J Cancer 112:738.
   PubMed Web of Science ®Google Scholar
• Baselga J. (2010). Treatment of HER2-overexpressing breast cancer. Ann Oncol 21:vii36.
   PubMed Web of Science ®Google Scholar
• Berezov A, Zhang HT, Greene MI, Murali R. (2001). Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem 44:2565.
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Brown E, et al. (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Therapeut 5:2676–84.
   PubMed Web of Science ®Google Scholar
• Chen B, Dai W, He B, et al. (2017). Current multistage drug delivery systems based on the tumor microenvironment. Theranostics 7:538.
   PubMed Web of Science ®Google Scholar
• Dent S, Oyan B, Honig A, et al. (2013). HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treatment Rev 39:622–31.
   PubMed Web of Science ®Google Scholar
• Fantin VR, Berardi MJ, Babbe H, et al. (2005). A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res 65:6891–900.
   PubMed Web of Science ®Google Scholar
• Gemmete JJ, Mukherji SK. (2011). Trastuzumab (herceptin). Ajnr. Am J Neuroradiol 32:1373.
   PubMed Web of Science ®Google Scholar
• Graff CP, Wittrup KD. (2003). Theoretical analysis of antibody targeting of tumor spheroids importance of dosage for penetration, and affinity for retention. Cancer Res 63:1288–96.
   PubMed Web of Science ®Google Scholar
• Guertin AD, Martin MM, Roberts B, et al. (2012). Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int 12:45.
   PubMed Web of Science ®Google Scholar
• Harari D, Yarden Y. (2000). Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102
   PubMed Web of Science ®Google Scholar
• Hassona Y, Cirillo N, Heesom K, et al. (2014). Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion. Br J Cancer 111:1230–7.
   PubMed Web of Science ®Google Scholar
• He H, Sun L, Ye J, et al. (2016). Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents. J Control Release 240:67.
   PubMed Web of Science ®Google Scholar
• Hill K, Seltzer W, Selzer W, et al. (2006). Useful reagents for introduction of Boc and Fmoc protective groups to amines: Boc-DMT and Fmoc-DMT. Cheminform 37:1931–3.
   Google Scholar
• Hortobágyi GN. (1997). Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl 4:1
   PubMed Web of Science ®Google Scholar
• Jodele S, Blavier L, Yoon JM, Declerck YA. (2006). Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 25:35–43.
   PubMed Web of Science ®Google Scholar
• Kiyomiya K, Matsuo S, Kurebe M. (2001). Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 61:2467.
   PubMed Web of Science ®Google Scholar
• Kojima C, Suehiro T, Watanabe K, et al. (2013). Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater 9:5673–80.
   PubMed Web of Science ®Google Scholar
• Le XF, Claret FX, Lammayot A, et al. (2003). The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278:23441.
   PubMed Web of Science ®Google Scholar
• Lee KS, Sun YR, Kim SJ, et al. (1996). Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 14:512–9.
   PubMed Web of Science ®Google Scholar
• Li S, Zhou Y, Wang R, et al. (2007). Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Therapeut 6:1031–8.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Pan W, Hu YJ, Wang YT. (2012). Multi-target drugs: the trend of drug research and development. PLoS One 7:e40262
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa SM, Campiglio M, Tagliabue E. (2003). Biologic and therapeutic role of HER2 in cancer. Oncogene 22:6570–8.
   PubMed Web of Science ®Google Scholar
• Milosevic Z, Pesic M, Stankovic T, et al. (2014). Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Translat Res J Lab Clin Med 164:411.
   Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229.
   PubMed Web of Science ®Google Scholar
• Morphy R, Kay C, Rankovic Z. (2004). From magic bullets to designed multiple ligands. Drug Discov Today 9:641
   PubMed Web of Science ®Google Scholar
• Myers AG, Gleason JL, Taeyoung Yoon A, Kung DW. (1997). Highly practical methodology for the synthesis of d- and l-α-amino acids, N-protected α-amino acids, and N-methyl-α-amino acids. Cheminform 119:656–73.
   Google Scholar
• Nagy A, Schally AV, Armatis P, et al. (1996). Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93:7269
   PubMed Web of Science ®Google Scholar
• Park BW, Zhang HT, Wu C, et al. (2000). Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 18:194.
   PubMed Web of Science ®Google Scholar
• Perron V, Abbott S, Moreau N, et al. (2009). ChemInform abstract: a method for the selective protection of aromatic amines in the presence of aliphatic amines. Cheminform 40:283–9.
   Google Scholar
• Rimawi MF, Schiff R, Osborne CK. (2015). Targeting HER2 for the treatment of breast cancer. Annu Rev Med 66:111
   PubMed Web of Science ®Google Scholar
• Rochette L, Guenancia C, Gudjoncik A, et al. (2015). Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36:326–48.
   PubMed Web of Science ®Google Scholar
• Saad S, Gottlieb DJ, Bradstock KF, et al. (2002). Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 62:283.
   PubMed Web of Science ®Google Scholar
• Sann CL. (2006). Maleimide spacers as versatile linkers in the synthesis of bioconjugates of anthracyclines. Cheminform 37:357.
   Google Scholar
• Schlage P, Mezo G, Orbán E, et al. (2011). Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J Control Release 156:170–8.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Xu J, You Y, et al. (2015). Acid-sensitive peptide-conjugated doxorubicin mediates the lysosomal pathway of apoptosis and reverses drug resistance in breast cancer. Mol Pharmaceut 12:2217.
   PubMed Web of Science ®Google Scholar
• Shi NQ, Gao W, Xiang B, Qi XR. (2012). Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int J Nanomed 7:1613.
   PubMed Web of Science ®Google Scholar
• Singh R, Whitesides GM. 1993. Thiol-disulfide interchange. Chichester, UK: John Wiley & Sons, Inc., 633–658.
   Google Scholar
• Smolensky D, Rathore K, Cekanova M. (2015). Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cellsin vitro. BMC Cancer 15:1–11.
   PubMed Web of Science ®Google Scholar
• Soudy R, Chen C, Kaur K. (2013). Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. J Med Chem 56:7564–73.
   PubMed Web of Science ®Google Scholar
• Tai W, Mahato R, Cheng K. (2010). The role of HER2 in cancer therapy and targeted drug delivery. J Controlled Release 146:264–75.
   PubMed Web of Science ®Google Scholar
• Takeda YS, Xu Q. (2015). Neuronal differentiation of human mesenchymal stem cells using exosomes derived from differentiating neuronal cells. PLoS One 10:e0135111.
   PubMed Web of Science ®Google Scholar
• Tan M, Lan KH, Yao J, et al. (2006). Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66:3764–72.
   PubMed Web of Science ®Google Scholar
• Tarcic G, Yarden Y. 2013. Antibody-mediated receptor endocytosis: harnessing the cellular machinery to combat cancer. New York: Springer.
   Google Scholar
• Tewey KM, Rowe TC, Yang L, et al. (1984). Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–8.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. (2008). Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57–61.
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Suzuki Y, Saito Y, Umemura S. (2009). The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 16:295–300.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 13:813.
   PubMed Web of Science ®Google Scholar
• Van Duijnhoven SM, Robillard MS, Nicolay K, Grüll H. (2011). Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med 52:279–86.
   PubMed Web of Science ®Google Scholar
• Wonders KY, Reigle BS. (2009). Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther 8:17–21.
   PubMed Web of Science ®Google Scholar
• Xu J, Liu Y, Yu Y, et al. (2012). Subcellular quantification of doxorubicin and its metabolite in cultured human leukemia cells using liquid chromatography-tandem mass spectrometry. Anal Lett 45:1980–94.
   Web of Science ®Google Scholar
• Yuan S, You Y, Yun C. (2016). Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer. Int J Pharmaceut 512:1–13.
   PubMed Web of Science ®Google Scholar
• Zhang N, Klegerman ME, Deng H, et al. (2013). Trastuzumab-doxorubicin conjugate provides enhanced anti-cancer potency and reduced cardiotoxicity. J Cancer Ther 4:308–22.
   Google Scholar
• Zhu L, Perche F, Wang T, Torchilin VP. (2014). Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of sirna and hydrophobic drugs. Biomaterials 35:4213.
   PubMed Web of Science ®Google Scholar